No fingersticks, full automation: FDA greenlights Medtronic’s new diabetes sensor, stock sentiment turns bullish
Medtronic wins FDA nod for its new Simplera Sync sensor—find out how this breakthrough is reshaping diabetes care and what it means for MDT stock. Read More
Brain cancer breakthrough? Telix Pharmaceuticals’ TLX101 boosts survival in early study as stock outlook strengthens
Discover how Telix’s TLX101 therapy is showing new promise for brain cancer as investor sentiment rises with key study results and clinical trial expansion. Read More
Faster sepsis diagnosis? Accelerate Diagnostics’ WAVE System may hold the key
Accelerate Diagnostics seeks FDA clearance for its WAVE system, a rapid AST solution for serious infections. Will approval boost its struggling stock? Read More
Danone faces quality concerns as FDA recalls International Delight coffee creamers
Danone North America has issued a voluntary recall of over 75,000 bottles of International Delight coffee creamer following reports of product spoilage and illness. The ... Read More
CEL-SCI advances Multikine study with FDA nod, eyes non-dilutive funding for commercial push
CEL-SCI Corporation has taken a significant step toward commercializing its investigational Multikine neoadjuvant therapy, as the U.S. Food and Drug Administration (FDA) review of its ... Read More
Guardant Health’s Shield blood test gains ADLT status, strengthening Medicare coverage for colorectal cancer screening
Guardant Health, Inc. has received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS) for its Shield blood test, ... Read More
Charlotte’s Web and DeFloria advance Autism treatment with FDA Phase 2 approval
Charlotte’s Web Holdings, Inc., a recognized leader in hemp-derived wellness products, has announced a major development in the pursuit of cannabinoid-based medical treatments. DeFloria, Inc., ... Read More
Mirum Pharmaceuticals gains FDA approval for Ctexli, the first drug for CTX
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved Ctexli (chenodiol) as the first treatment for cerebrotendinous xanthomatosis (CTX), a rare ... Read More
Harmony Biosciences faces FDA setback for pitolisant in idiopathic hypersomnia
Harmony Biosciences Holdings, Inc. has encountered a regulatory hurdle in its efforts to expand the use of pitolisant for the treatment of excessive daytime sleepiness ... Read More
Clarity Pharmaceuticals bags FDA fast track designation for prostate cancer candidate 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Fast Track Designation to 67Cu-SAR-bisPSMA, a targeted ... Read More